Literature DB >> 16183272

Angiogenesis inhibitors derived from thalidomide.

Tomomi Noguchi1, Haruka Fujimoto, Hiroko Sano, Atsushi Miyajima, Hiroyuki Miyachi, Yuichi Hashimoto.   

Abstract

5-Hydroxy-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33: 10), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent anti-angiogenic activity in a human umbilical vein endothelial cell (HUVEC) assay. Thalidomide (1) and its metabolite, 5-hydroxythalidomide (5-HT: 2), which possesses a hydroxyl group at the position corresponding to that of 5HPP-33, as well as IMiDs (immunomodulatory derivatives of thalidomide: 3 and 5), also showed weak or moderate activity in the same assay.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16183272     DOI： 10.1016/j.bmcl.2005.08.086

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  11 in total

1.  Screening for angiogenic inhibitors in zebrafish to evaluate a predictive model for developmental vascular toxicity.

Authors:  Tamara Tal; Claire Kilty; Andrew Smith; Carlie LaLone; Brendán Kennedy; Alan Tennant; Catherine W McCollum; Maria Bondesson; Thomas Knudsen; Stephanie Padilla; Nicole Kleinstreuer
Journal:  Reprod Toxicol       Date:  2016-12-19       Impact factor: 3.143

2.  Systems Modeling of Developmental Vascular Toxicity.

Authors:  Katerine S Saili; Jill A Franzosa; Nancy C Baker; Robert G Ellis-Hutchings; Raja S Settivari; Edward W Carney; Richard Spencer; Todd J Zurlinden; Nicole C Kleinstreuer; Shuaizhang Li; Menghang Xia; Thomas B Knudsen
Journal:  Curr Opin Toxicol       Date:  2019-06-01

3.  Levofloxacin Cocrystal/Salt with Phthalimide and Caffeic Acid as Promising Solid-State Approach to Improve Antimicrobial Efficiency.

Authors:  Noor Ul Islam; Muhammad Naveed Umar; Ezzat Khan; Fakhria A Al-Joufi; Shaymaa Najm Abed; Muhammad Said; Habib Ullah; Muhammad Iftikhar; Muhammad Zahoor; Farhat Ali Khan
Journal:  Antibiotics (Basel)       Date:  2022-06-13

Review 4.  Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Authors:  Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

Review 5.  Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.

Authors:  Xiubao Chang; Yuanxiao Zhu; Changxin Shi; A Keith Stewart
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2013-12-29       Impact factor: 3.848

6.  Environmental impact on vascular development predicted by high-throughput screening.

Authors:  Nicole C Kleinstreuer; Richard S Judson; David M Reif; Nisha S Sipes; Amar V Singh; Kelly J Chandler; Rob Dewoskin; David J Dix; Robert J Kavlock; Thomas B Knudsen
Journal:  Environ Health Perspect       Date:  2011-07-25       Impact factor: 9.031

7.  Design and Synthesis of 4-flurophthalimides as potential anticonvulsant agents.

Authors:  Maryam Iman; Sina Fakhari; Mohammad Jahanpanah; Nima Naderi; Asghar Davood
Journal:  Iran J Pharm Res       Date:  2018       Impact factor: 1.696

8.  A computational model predicting disruption of blood vessel development.

Authors:  Nicole Kleinstreuer; David Dix; Michael Rountree; Nancy Baker; Nisha Sipes; David Reif; Richard Spencer; Thomas Knudsen
Journal:  PLoS Comput Biol       Date:  2013-04-04       Impact factor: 4.475

9.  Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.

Authors:  Qinqin Xu; Yue-xian Hou; Paul Langlais; Patrick Erickson; James Zhu; Chang-Xin Shi; Moulun Luo; Yuanxiao Zhu; Ye Xu; Lawrence J Mandarino; Keith Stewart; Xiu-bao Chang
Journal:  BMC Cancer       Date:  2016-05-03       Impact factor: 4.430

10.  Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity.

Authors:  Ahmed A E Mourad; Mai A E Mourad; Peter G Jones
Journal:  Drug Des Devel Ther       Date:  2020-08-03       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.